会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明申请
    • A METHOD FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
    • 一种重组人类血红蛋白和纤维蛋白原的制备方法
    • WO2007103447A2
    • 2007-09-13
    • PCT/US2007/005845
    • 2007-03-06
    • HUMAGENE, INC.OSHTER, Kurt
    • OSHTER, Kurt
    • A61K31/405
    • C07K14/745
    • The present invention discloses a novel method for the preparation of recombinant human proteins expressed in human cells. Specifically, the present invention relates to novel methods for the preparation of human recombinant thrombin and human recombinant fibrinogen. Moreover, the method employs serum-free culturing conditions and therefore provides recombinant human proteins expressed in human cells of increased safety to the patient when used in human medical treatments. In addition, the immunogenic response to the recombinant human proteins expressed in human cells may be lower. Human recombinant thrombin is expressed in the human embryonic kidney 293 cell line and the protein can be prepared using two different routes, one starting from a point mutated prothrombin with gla and Kringle 1 and 2 domains, and maintaining these domains during the process; the other one starting with prothrombin (non-mutated), via a prethrombin with a HPC4-Kringle 2 domain and subjecting this prethrombin to a point mutation. Human recombinant fibrinogen is expressed in the human embryonic kidney 293 cell line.
    • 本发明公开了一种在人细胞中表达的重组人蛋白质的制备方法。 具体地说,本发明涉及制备人重组凝血酶和人重组纤维蛋白原的新方法。 此外,该方法使用无血清培养条件,因此当在人类医学治疗中使用时,向患者提供在人细胞中表达增强安全性的重组人蛋白质。 此外,对在人细胞中表达的重组人蛋白的免疫原性应答可能较低。 人重组凝血酶在人胚胎肾293细胞系中表达,蛋白质可以使用两种不同的途径制备,一种是从具有gla和Kringle 1和2结构域的突变型凝血酶原点开始,并在该过程中维持这些结构域; 另一个从凝血酶原(非突变)开始,通过具有HPC4-Kringle2结构域的凝血酶原并使该凝血酶原发生点突变。 人重组纤维蛋白原在人胚肾293细胞系中表达。